<DOC>
	<DOCNO>NCT00516802</DOCNO>
	<brief_summary>This Phase I , open-label , dose-escalating , study safety tolerability KU-0059436 combination DTIC treatment patient advance melanoma previously receive systemic cytotoxic chemotherapy .</brief_summary>
	<brief_title>A Study Assess Safety Pharmacokinetics Inhibitor PARP Combination With Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Patients must : 1 . Unresectable stage 3 stage 4 cutaneous melanoma unknown primary melanoma metastasis . 2 . Histological cytological confirmation melanoma . Histological confirmation melanoma primary site suffice , unless primary site unknown . Previous treatment cytotoxic chemotherapy advance melanoma , apart treatment melanoma isolate limb perfusion . Radiotherapy ( except palliative reason ) , endocrine therapy , immunotherapy use investigational agent within 4 week prior trial entry ( long period depend defined characteristic agent use ) . Major surgery within 4 week start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>dacarbazine</keyword>
</DOC>